The bestselling drugs of 2018 in the USD 485 billion US pharma market. The list features several major blockbusters benefiting from the delays in biosimilar approval in the US, as well as several small-molecule medications that stand to lose out to generic competition in the coming years. AbbVie's Humira is way out in front, earning USD 13.68 billion, more than double that of its nearest competitor, Celgene's Revlimid, which made USD 6.47 billion.  

Made with Visme Infographic Maker